SITE MAP | ABOUT US

References

Section Navigator> References>
                                                              > Journals
                                                              > Websites
                                                              > Other


Primary and review articles

  • Abid K, Soto C. The intriguing prion disorders. Cell. Mol. Life Sci 2006; 63: 2342-2351.

  • Akder VM, Zeiler B, Kryukov V, Kascsak R, Rubenstein R, Grossman A. Small, Highly Structured RNAs Participate in the Conversion of Human Recombinant PrpSen to PrpRes in Vitro. J. Mol. Biol. 2003; 332:47-57.

  • Baker CA, Manuelidis L. Unique inflammatory RNA profiles of microglia in Creutzfeldt-Jakob disease. PNAS. 2003; 100(2): 675-679.

  • Baker CA, Martin D, Manuelidis L. Microglia from Creutzfeldt-Jakob disease-infected brains are infectious and show specific mRNA activation profiles. Journal of Virology. 2002; 76(21):10905-10913.

  • Blakrishnan K, Maio AD. Heat shock protein 70 binds its own messenger ribonucleic acid as part of a gene expression self-limiting mechanism. Cell Stress and Chaperones. 2006; 11(1): 44-50.

  • Bunka DHJ, Stockley PG. Aptamers come of age – at last. Nature Reviews Microbiology 2006; 4:588-596.

  • Crist CG, Nakamura Y. Cross-Talk between RNA and Prions. Journal of Biochemistry 2006; 140: 167-173.

  • Daude N, Marella M, Chabry J. Specific inhibition of pathological prion protein accumulation by small interfering RNAs. Journal of Cell Science 2003; 116: 2775-2779.

  • Deleault NR, Lucassen RW, Supattapone S. RNA molecules stimulate prion protein conversion. Nature 2003;425:727-720.

  • Golding MC, Long CR, Carmell MA, Hannon GJ, Westhusin ME, Suppression of prion protein in livestock by RNA interference. PNAS 2006; 103: 5285-5290.

  • Jayasena, SD. Aptamers: An Emerging Class of Molecules That Rival Antibodies in Diagnostics. Clinical Chemistry 1999; 45:1628-1650.

  • Kong Q. RNAi: a novel strategy for the treatment of prion diseases. The Journal of Clinical Investigation 2006; 116: 3101-3103.

  • Lu LY, Baker CA, Manuelidis L. New Molecular Markers of Early and Progressive CJD Brain Infection. Journal of Cellular Biochemistiry. 2004; 93: 644-652.

  • Mabbott NA, MacPherson GG. Prions and their lethal journey to the brain. Nature. 2006; 4: 201-211.

  • Mallucci G, Dickinson A, Linehan J, Klohn PC, Brandner S, Collinge J. Depleting Neuronal Prp in Prion Infection Prevents Disease and Reverses Spongiosis. Science 2003; 302:871-874.

  • Marella M, Chabry J. Neurons and astrocytes respond to Prion infection by inducing microglia recruitment. The Journal of Neuroscience. 2004; 24(3): 620-627.

  • Mercey, R. Lantier I, Maurel MC, Grosclaude J, Lantier F, Marc D. Fast, reversible interaction of prion protein with RNA aptamers containing specific sequence patterns. Archives of Virology 2006; 151:2197-2214.

  • Nandi PK. Prions at the crossroads: the need to identify the active TSE agent. BioEssay 2004; 26:469-473.

  • Pfeifer A, Eigenbrod S, Al-Khadra S, Hofmann A, Mitteregger G, Moser M, Bertsch U, Kretzschmar H. Lentivector-mediated RNAi efficiently suppresses prion protein and prolongs survival of scrapie-infected mice. The Journal of Clinical Investigation 2006; 116: 3204-3210.

  • Proske D, Gilch S, Wopfner F, Schatzl HM, Winnacker EL, Famulok M. Prion-protein-specific aptamer reduces PrPsc formation. ChemBioChem 2002; 3:717-725.

  • Rhie A, Kirby L, Sayer N, Wellesley R, Disterer P, Sylvester I, Gill A, Hope J, James W, Tahiri-Alaoui A. Characterization of 2'-flouro-RNA aptamers that bind preferentially to disease-associated conformations of prion protein and inhibit conversion. The Journal of Biological Chemistry 2003; 278:39697-39705.

  • Richt JA, Kasinathan P, Hamir AN, Castilla J, Sathiyaseelan T, Vargas F, Sathiyaseelan J, Wu H, Matsushita H, Koster J, Kato S, Ishida I, Soto C, Robl JM, Kuroiwa Y. Production of cattle lacking prion protein. Nature Biotechnology 2007; 25: 132-138.

  • Saborio GP, Permanne B, Soto C. Sensitive detection of pathological prion protein by cyclicamplification of protein misfolding. Nature 2001; 411:810-813.

  • Sachdeva G, D’Costa J, Cho JE, Kachapati K, Choudhry V, Arya SK. Chimeric HIV-1 and HIV-2 Lentiviral Vectors With Added Safety Insurance. Journal of Medical Virology 2007; 79: 118-126.

  • Sayer NM, Cubin M, Rhie A, Bullock M, Tahiri-Alaoui A, James W. Structural determinants of conformationally selective, prion-binding aptamers. The Journal of Biological Chemistry 2004; 279:13102-13109.

  • Sekiya S, Noda K, Nishikawa F, Yokoyama T, Kumar PKR, Nishikawa S. Characterization and application of a novel RNA aptamer against the mouse prion protein. J. Biochem. 2006; 139:383-390.

  • Shyu W, Kao M, Chou W, Hsu Y, Soong B. Creutzfeldt-Jakob disease: heat shock protein 70 mRNA levels in mononuclear blood cells and clinical study. J Neurol. 2000; 247: 929-934.

  • Snove O, Rossi JJ. Expressing short harpin RNAs in vivo. Nat. Methods 2006; 3: 689-695.

  • Supattapone S. Prion protein conversion in vitro. J. Mol. Biol. 2004; 82: 348-356.

  • Tilly G, Chapuis J, Vilette D, Laude H, Vilotte JL. Efficient and specific down-regulation of prion protein expression by RNAi. Biochemical & Biophysical Research Communication 2003; 305: 548-551.

  • Vasan S, Mong PY, Grossman A. Interaction of Prion Protein with Small Highly Structured RNAs: Detection and Characterization of Prp-Oligomers. Neurochem Res 2006; 31: 629-637. Watts JC, Balachandran A, Westaway D. The Expanding Universe of Prion Diseases. PloS Pathogens 2006; 2:152-163.

  • Weise J, Sandau R, Schwarting S, Crome O, Wrede A, Schulz-Schaeffer W, Zerr I, Bähr M. Deletion of Cellular Prion Protein Results in Reduced Akt Activation, Enhanced Postischemic Caspase-3 Activation, and Exacerbation of Ischemic Brain Injury. Stroke 2006; 37: 1296-1300.

  • Xia XG, Zhou H, Xu Z. Promises and challenges in developing RNAi as a research tool and therapy for neurodegenerative diseases. Neurodegener. Dis. 2005; 2: 220-231.

Textbooks

  • Alberts B, Johnson A, Lewis J, Raff M, Roberts K, and Walter P. Molecular Biology of the Cell. 4th ed. New York: Garland Publishing; 2002. pp 31, 362-363.

Websites

  • Alberta Prion Research Institute. [Internet] Why Prion Research?(Canada) [date unknown]- [cited 2007 Mar12] Available from: http://www.prioninstitute.ca/basics.aspx?section=4&header=prions3

  • Department of Argricultural and Resource Economics, University of California [data base on the Internet]. Carter CA et al: Giannini Foundation of Agricultural Economics (US) Market Effects of Searching for Mad Cows. 2004 Sept/Oct - [cited 2007 Mar 12] Available from: http://www.agecon.ucdavis.edu/outreach/update_articles/v8n1_3.pdf

  • Prevention News Update Database [Internet]. Centers for Disease Control and Prevention (US), Public Health Service Recommendations for the Use of Vaccines Manufactured with Bovine-Derived Materials. 2000 Dec - [cited 2007 Mar 12]. Available from: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4950a4.htm

  • United States Department of Argriculture Animal and Plant Health Inspection Service [Internet]. BSE Photo Gallery(US)-2007 Mar- [cited Mar12] Available from: http://www.aphis.usda.gov/newsroom/hot_issues/bse/index.shtml

  • Wikimedia Inc. [Internet] Wikipedia (US): Prion Proteins. 2007 Mar-[cited 2007 Mar 12] Available from: http://en.wikipedia.org/wiki/Prion_protein
Copyright © 2007 RNA BASED PRION RESEARCH GROUP
The information and opinions shown here represent those of students of BIO349 and
are not necessarily those of the University of Toronto.